Alebund Pharmaceuticals Raises $54.5 Million In Series B+ Financing Round To Fuel Development Of Renal Disease Treatment
Alebund Pharmaceuticals Raises $54.5 Million In Series B+ Financing Round To Fuel Development Of Renal Disease Treatment
09/14/21, 12:03 AM
Location
shanghaiMoney raised
$54.5 million
Round Type
series b
Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has secured $54.5 million in its Series B+ financing round. This round was led by 3H Health Investment, Loyal Valley Capital and Morningside Ventures, followed by YuanBio Venture Capital, Octagon Capital, Verition Fund Management and HT Capital. Existing Shareholders including Lilly Asia Ventures, Quan Capital, a prominent sovereign wealth fund, 3E Bioventures Capital and Sherpa Healthcare Partners also took part in the financing. Proceeds raised in this round will help accelerate the development of Alebund's clinical programs, the construction of the manufacturing site, the research of pre-clinical assets, and the expansion of Company's talent pool.
Company Info
Location
shanghai, shanghai, china
Additional Info
Alebund is a clinical stage biopharmaceutical company and is dedicated to the discovery and development of novel therapies and to providing better clinical solutions to patients with kidney diseases and related chronic conditions.
Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease (ADPKD). Alehund's pipeline comprises both small-molecule and biologic assets.